These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 8476755)

  • 1. Structure-activity relationships and binding model of novel aromatase inhibitors.
    Lang M; Batzl C; Furet P; Bowman R; Häusler A; Bhatnagar AS
    J Steroid Biochem Mol Biol; 1993 Mar; 44(4-6):421-8. PubMed ID: 8476755
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design and synthesis of a new type of non steroidal human aromatase inhibitors.
    Sonnet P; Guillon J; Enguehard C; Dallemagne P; Bureau R; Rault S Auvray P; Moslemi S; Sourdiane P; Galopin S; Séralini GE
    Bioorg Med Chem Lett; 1998 May; 8(9):1041-4. PubMed ID: 9871704
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of Fadrozole (CGS 16949A) and Letrozole (CGS 20267) on the inhibition of aromatase activity in breast cancer patients.
    Demers LM
    Breast Cancer Res Treat; 1994; 30(1):95-102. PubMed ID: 7949208
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Aromatase inhibitors: pharmacological aspects].
    de Crémoux P
    Bull Cancer; 2000 Dec; 87 Spec No():23-29. PubMed ID: 11250605
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aromatase inhibitors: synthesis, biological activity, and binding mode of azole-type compounds.
    Furet P; Batzl C; Bhatnagar A; Francotte E; Rihs G; Lang M
    J Med Chem; 1993 May; 36(10):1393-400. PubMed ID: 8496907
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 1-[(Benzofuran-2-yl)phenylmethyl]-triazoles and -tetrazoles - potent competitive inhibitors of aromatase.
    Vinh TK; Ahmadi M; Delgado PO; Perez SF; Walters HM; Smith HJ; Nicholls PJ; Simons C
    Bioorg Med Chem Lett; 1999 Jul; 9(14):2105-8. PubMed ID: 10450990
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reversible inhibition of human placental microsomal aromatase by CGS 18320B and other non-steroidal compounds.
    Bullion KA; Osawa Y; Braun DG
    Endocr Res; 1990; 16(2):255-67. PubMed ID: 2140551
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Highly selective inhibition of estrogen biosynthesis by CGS 20267, a new non-steroidal aromatase inhibitor.
    Bhatnagar AS; Häusler A; Schieweck K; Lang M; Bowman R
    J Steroid Biochem Mol Biol; 1990 Dec; 37(6):1021-7. PubMed ID: 2149502
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fadrozole and letrozole in advanced breast cancer: clinical and biochemical effects.
    Smith IE; Norton A
    Breast Cancer Res Treat; 1998; 49 Suppl 1():S67-71; discussion S73-7. PubMed ID: 9797020
    [No Abstract]   [Full Text] [Related]  

  • 10. Mechanisms of the actions of aromatase inhibitors 4-hydroxyandrostenedione, fadrozole, and aminoglutethimide on aromatase in JEG-3 cell culture.
    Yue W; Brodie AM
    J Steroid Biochem Mol Biol; 1997; 63(4-6):317-28. PubMed ID: 9459198
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of the aromatase inhibitor, rogletimide (pyridoglutethimide), on guinea pig adrenal cell steroidogenesis and placental microsomal aromatase activity: comparison with aminoglutethimide and CGS 16949A.
    Newton CJ; Mehta A; Dowsett M
    J Steroid Biochem Mol Biol; 1991 Nov; 39(5A):723-7. PubMed ID: 1659868
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intracellular aromatase and its relevance to the pharmacological efficacy of aromatase inhibitors.
    Bhatnagar AS; Brodie AM; Long BJ; Evans DB; Miller WR
    J Steroid Biochem Mol Biol; 2001; 76(1-5):199-202. PubMed ID: 11384878
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Are differences in the available aromatase inhibitors and inactivators significant?
    Johnson PE; Buzdar A
    Clin Cancer Res; 2001 Dec; 7(12 Suppl):4360s-4368s; discussion 4411s-4412s. PubMed ID: 11916226
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fast three dimensional pharmacophore virtual screening of new potent non-steroid aromatase inhibitors.
    Neves MA; Dinis TC; Colombo G; Sá e Melo ML
    J Med Chem; 2009 Jan; 52(1):143-50. PubMed ID: 19072235
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative molecular field analysis of non-steroidal aromatase inhibitors related to fadrozole.
    Recanatini M
    J Comput Aided Mol Des; 1996 Feb; 10(1):74-82. PubMed ID: 8786417
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure-activity studies of non-steroidal aromatase inhibitors: the crystal and molecular structures of CGS 16949A and CGS 18320B.
    Van Roey P; Bullion KA; Osawa Y; Browne LJ; Bowman RM; Braun DG
    J Enzyme Inhib; 1991; 5(2):119-32. PubMed ID: 1669441
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aromatase inhibitors--mechanisms for non-steroidal inhibitors.
    Vanden Bossche HV; Moereels H; Koymans LM
    Breast Cancer Res Treat; 1994; 30(1):43-55. PubMed ID: 7949204
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Preclinical evaluation of aromatase inhibitors antitumor activity].
    Auvray P; Bichat F; Genne P
    Bull Cancer; 2000 Dec; 87 Spec No():7-22. PubMed ID: 11250604
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potency and specificity of CGS-16949A as an aromatase inhibitor.
    Santen RJ; Langecker P; Santner SJ; Sikka S; Rajfer J; Swerdloff R
    Endocr Res; 1990; 16(1):77-91. PubMed ID: 2139412
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel aromatase inhibitors.
    Bhatnagar AS; Häusler A; Schieweck K; Browne LJ; Bowman R; Steele RE
    J Steroid Biochem Mol Biol; 1990 Nov; 37(3):363-7. PubMed ID: 2147860
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.